The study, published March 12 in JAMA Network Open, compared the newly approved tenecteplase in a single quick injection to alteplase, the stroke treatment that has been used for decades and requires an hourlong infusion.
Researchers analyzed data from an American Heart Association registry, examining more than 79,000 stroke patients. Outcomes for those treated with tenecteplase were comparable to those who received alteplase, with potential benefits for patients who cannot undergo clot removal procedures, according to the study.
The FDA approved tenecteplase in early March as an alternative to alteplase due to emerging evidence of safety and effectiveness of the alternative through stroke centers publishing their experience through clinical trials.
Because tenecteplase is administered in a single, quick injection, this could speed up treatment and reduce delays in procedures such as endovascular thrombectomy, which removes blood clots.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
